DNA methylation detection: detecting the methylation status of colorectal cancer specimen
Study summary
This study aims to evaluate the predictive value of a four-gene methylation assay called Guangzhou Panel in early-stage colorectal cancer. Patients will be divided into two groups: high risk group and low risk group. The primary endpoint is 5 year disease free survival (DFS).
Eligibility
Sex
ALL
Min age
40 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
1. TNM stage I-II (T1-4N0M0) colorectal cancer cases
2. receive radical surgical resection
3. have completed data of tumor location, histological type, behavioral characteristics or TNM staging
4. have tumor specimens and either a valid microsatellite instability (MSI) or immuno-histochemistry (IHC) data
5. have valid V-raf murine sarcoma viral oncogene homolog B1 (BRAF), kirsten rat sarcoma viral oncogene (KRAS), CpG island methylator phenotype (CIMP) results
6. have at least 4 years of follow-up
7. have valid time to local recurrence/metastasis in follow-up
8. have clinical/treatment record data and valid preoperative status of intestinal obstruction or perforation (IOP), counts of lymph node removed in surgical resection.
Exclusion Criteria:
1. have had a previous diagnosis of any cancer or presence of any tumor other than the CRC
2. have had inflammatory bowel disease
3. have had hereditary colorectal cancer syndromes, including Familial adenomatous polyposis, mutyh (MYH)-associated polyposis, Peutz-Jeghers syndrome, Juvenile polyposis coli, phosphate and tension homology deleted on chromosome ten (PTEN) tumor-hamartoma syndromes, Lynch Syndrome, and Familial Colorectal Cancer Type X.
Primary outcome measure(s)
disease free survival — From date of operation until the date of first recurrence or date of death from any cause, whichever came first, assessed up to 5 years the length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer
Trial sites (1)
Facility
City
Region
Status
The Sixth Affiliate Hospital of Sun Yat-Sen University
Guangzhou
Guangdong
More Sixth Affiliated Hospital, Sun Yat-sen University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.